Search for "carboline" in Full Text gives 31 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2023, 19, 349–379, doi:10.3762/bjoc.19.29
Graphical Abstract
Figure 1: Alkyne–azide "click reaction".
Figure 2: β- and meso-triazole-linked porphyrin.
Scheme 1: Synthesis of β-triazole-linked porphyrins 3a–c.
Scheme 2: Synthesis of β-triazole-bridged porphyrin-coumarin conjugates 11–20.
Scheme 3: Synthesis of β-triazole-bridged porphyrin-xanthone conjugates 23–27 and xanthone-bridged β-triazolo...
Scheme 4: Synthesis of meso-triazoloporphyrins 32a–c and triazole-bridged diporphyrins 34.
Scheme 5: Synthesis of meso-triazole-linked porphyrin-ferrocene conjugates 37a–d.
Scheme 6: Synthesis of meso-triazole-linked porphyrin conjugates 40a,b and 41a,b.
Scheme 7: Synthesis of meso-triazole-linked glycoporphyrins 43a–c.
Scheme 8: Synthesis of meso-triazole-linked porphyrin-coumarin conjugates 44–48.
Scheme 9: Synthesis of meso-triazole-bridged porphyrin-DNA conjugate 50.
Scheme 10: Synthesis of meso-linked porphyrin-triazole conjugates 53 and 57.
Scheme 11: Synthesis of meso-triazole-linked porphyrin-corrole conjugate 60.
Scheme 12: Synthesis of porphyrin conjugates 64a,b and 67a,b. Reaction conditions: (i) CuSO4, sodium ascorbate...
Scheme 13: Synthesis of meso-triazole-bridged porphyrin-quinolone conjugates 70a–e.
Scheme 14: Synthesis of meso-triazole-linked porphyrin-fluorescein dyad 73.
Scheme 15: Synthesis of meso-triazole-linked porphyrin-carborane conjugates 76a,b.
Scheme 16: Synthesis of meso-triazole-bridged porphyrin-BODIPY conjugates 78 and 80.
Scheme 17: Synthesis of meso-triazole-linked cationic porphyrin conjugates 85 and 87. Reaction conditions: (i)...
Scheme 18: Synthesis of meso-triazole-cobalt-porphyrin diimine-dioxime conjugate 91. Reactions conditions: (i)...
Scheme 19: Synthesis of triazole-linked porphyrin-bearing N-doped graphene hybrid 96.
Scheme 20: Synthesis of meso-triazole-linked porphyrin-fullerene dyads 100a–d and 104a,b.
Scheme 21: Synthesis of meso-triazole-bridged diporphyrin conjugates 107 and 108.
Scheme 22: Synthesis of porphyrin-ruthenium (II) conjugates 112a,b and 116a,b. Reaction conditions: (i) Zn(OAc)...
Scheme 23: Synthesis of meso-triazole-linked porphyrin dyad 119 and triad 121.
Scheme 24: Synthesis of di-triazole-bridged porphyrin-β-CD conjugate 126.
Scheme 25: Synthesis of meso-triazole-bridged porphyrin star trimer 129.
Scheme 26: Synthesis of 1,2,3-triazole-linked porphyrin-β-CD conjugates 131a,b.
Scheme 27: Synthesis of tritriazole-bridged porphyrin-lantern-DNA sequence 134.
Scheme 28: Synthesis of meso-triazole-linked porphyrin-polymer conjugates 137 and 139.
Scheme 29: Synthesis of triazole-linked capped porphyrin 142; Reaction conditions: method A: 10% H2O in THF, C...
Scheme 30: Synthesis of meso-tetratriazole-linked porphyrin-maleimine conjugates 145a–c.
Scheme 31: Synthesis of meso-tetratriazole-linked porphyrin-cholic acid complex 148a,b.
Scheme 32: Synthesis of meso-tetratriazole-linked porphyrin conjugates 151–153.
Scheme 33: Synthesis of meso-tetratrizole-porphyrin-carborane conjugates 155, 156 and 158a–c.
Scheme 34: Synthesis of meso-tetratriazole-porphyrin-cardanol conjugates 160 and 162.
Scheme 35: Synthesis of meso-tetratriazole-linked porphyrin-BODIPY conjugate 164.
Scheme 36: Synthesis of meso-tetratriazole-linked porphyrin-β-CD conjugates 166a,b.
Scheme 37: Synthesis of tetratriazole-bridged meso-arylporphyrins 171a–c and 172a–c.
Scheme 38: Synthesis of octatriazole-bridged porphyrin-β-CD conjugate 174 and porphyrin-adamantane conjugates ...
Beilstein J. Org. Chem. 2022, 18, 926–934, doi:10.3762/bjoc.18.92
Graphical Abstract
Figure 1: Few examples of β-carboline-based drugs and bioactive natural products.
Figure 2: 1/3-Formyl-9H-β-carboline: new synthons for the synthesis of β-carboline-fused and substituted fram...
Figure 3: A summary of previous reports toward exploration of 3-formyl-9H-β-carbolines.
Scheme 1: Synthesis of 3-formyl-9H-pyrido[3,4-b]indole derivatives.
Scheme 2: Synthesis of C-3 substituted pyrido[3,4-b]indole MBH derivatives (7 and 8).
Scheme 3: Synthesis of C-3 substituted pyrido[3,4-b]indole MBH derivatives 10.
Figure 4: Library of C-3-substituted pyrido[3,4-b]indole MBH derivatives 7, 8 and 10.
Figure 5: Results of optimization for fluorescence studies: a) contact time; b) concentration; c) solvent.
Figure 6: Pictorial representation of structure–fluorescence activity relationship of C-3 substituted pyrido[...
Beilstein J. Org. Chem. 2022, 18, 37–52, doi:10.3762/bjoc.18.4
Graphical Abstract
Scheme 1: Starch-immobilized ruthenium trichloride-catalyzed cyanation of tertiary amines.
Scheme 2: Proposed mechanism for the cyanation of tertiary amines using starch-immobilized ruthenium trichlor...
Scheme 3: Cyanation of tertiary amines using heterogeneous Ru/C catalyst.
Scheme 4: Proposed mechanism for cyanation of tertiary amines using a heterogeneous Ru/C catalyst.
Scheme 5: Ruthenium-carbamato complex-catalyzed oxidative cyanation of tertiary amines.
Scheme 6: Cyanation of tertiary amines using immobilized MCM-41-2N-RuCl3 as the catalyst.
Scheme 7: Cyanation of tertiary amines using RuCl3·nH2O as the catalyst and molecular oxygen as oxidant.
Scheme 8: RuCl3-catalyzed cyanation of tertiary amines using NaCN/HCN and H2O2 as oxidant.
Scheme 9: Proposed mechanism for the ruthenium-catalyzed oxidative cyanation using H2O2.
Scheme 10: Proposed mechanism for the ruthenium-catalyzed aerobic oxidative cyanation.
Scheme 11: RuCl3-catalyzed oxidative cyanation of tertiary amines using acetone cyanohydrin as the cyanating a...
Scheme 12: Cyanation of indoles using K4[Fe(CN)6] as cyano source and Ru(III)-exchanged NaY zeolite (RuY) as c...
Scheme 13: Cyanation of arenes and heteroarenes using a ruthenium(II) catalyst and N-cyano-N-phenyl-p-toluenes...
Scheme 14: Proposed mechanism for the cyanation of arenes and heteroarenes using ruthenium(II) as catalyst and...
Scheme 15: Synthesis of N-(2-cyanoaryl)-7-azaindoles.
Figure 1: Structure of the TiO2-immobilized ruthenium polyazine complex.
Scheme 16: Visible-light-induced oxidative cyanation of aza-Baylis–Hillman adducts.
Scheme 17: Synthesis of 1° alkyl nitriles using [Ru(bpy)3](PF6)2 as the photocatalyst.
Scheme 18: Synthesis of 2° and 3° alkyl nitriles using [Ru(bpy)3](PF6)2 as the photocatalyst.
Scheme 19: Photoredox cross coupling reaction.
Scheme 20: Synthesis of α-amino nitriles from amines via a one-pot strategy.
Scheme 21: Proposed mechanistic pathway for the cyanation of the aldimine intermediate.
Scheme 22: Strecker-type functionalization of N-aryl-substituted tetrahydroisoquinolines under flow conditions....
Scheme 23: One-pot synthesis of α-aminonitriles using RuCl3 as catalyst.
Scheme 24: Synthesis of alkyl nitriles using (Ru(TMHD)3) as the catalyst.
Scheme 25: Synthesis of cyanated isoxazolines from alkenyl oximes catalyzed by [RuCl2(p-cymene)]2 in the prese...
Scheme 26: Proposed mechanism for the synthesis of cyanated isoxazolines from alkenyl oximes.
Scheme 27: Oxidative cyanation of differently substituted alcohols.
Beilstein J. Org. Chem. 2021, 17, 1849–1938, doi:10.3762/bjoc.17.126
Graphical Abstract
Scheme 1: Schematic overview of transition metals studied in C–H activation processes.
Scheme 2: (A) Known biological activities related to benzimidazole-based compounds; (B and C) an example of a...
Scheme 3: (A) Known biological activities related to quinoline-based compounds; (B and C) an example of a sca...
Scheme 4: (A) Known biological activities related to sulfur-containing compounds; (B and C) an example of a s...
Scheme 5: (A) Known biological activities related to aminoindane derivatives; (B and C) an example of a scand...
Scheme 6: (A) Known biological activities related to norbornane derivatives; (B and C) an example of a scandi...
Scheme 7: (A) Known biological activities related to aniline derivatives; (B and C) an example of a titanium-...
Scheme 8: (A) Known biological activities related to cyclohexylamine derivatives; (B) an example of an intram...
Scheme 9: (A) Known biologically active benzophenone derivatives; (B and C) photocatalytic oxidation of benzy...
Scheme 10: (A) Known bioactive fluorine-containing compounds; (B and C) vanadium-mediated C(sp3)–H fluorinatio...
Scheme 11: (A) Known biologically active Lythraceae alkaloids; (B) synthesis of (±)-decinine (30).
Scheme 12: (A) Synthesis of (R)- and (S)-boehmeriasin (31); (B) synthesis of phenanthroindolizidines by vanadi...
Scheme 13: (A) Known bioactive BINOL derivatives; (B and C) vanadium-mediated oxidative coupling of 2-naphthol...
Scheme 14: (A) Known antiplasmodial imidazopyridazines; (B) practical synthesis of 41.
Scheme 15: (A) Gold-catalyzed drug-release mechanism using 2-alkynylbenzamides; (B and C) chromium-mediated al...
Scheme 16: (A) Examples of anti-inflammatory benzaldehyde derivatives; (B and C) chromium-mediated difunctiona...
Scheme 17: (A and B) Manganese-catalyzed chemoselective intramolecular C(sp3)–H amination; (C) late-stage modi...
Scheme 18: (A and B) Manganese-catalyzed C(sp3)–H amination; (C) late-stage modification of a leelamine deriva...
Scheme 19: (A) Known bioactive compounds containing substituted N-heterocycles; (B and C) manganese-catalyzed ...
Scheme 20: (A) Known indoles that present GPR40 full agonist activity; (B and C) manganese-catalyzed C–H alkyl...
Scheme 21: (A) Examples of known biaryl-containing drugs; (B and C) manganese-catalyzed C–H arylation through ...
Scheme 22: (A) Known zidovudine derivatives with potent anti-HIV properties; (B and C) manganese-catalyzed C–H...
Scheme 23: (A and B) Manganese-catalyzed C–H organic photo-electrosynthesis; (C) late-stage modification.
Scheme 24: (A) Example of a known antibacterial silylated dendrimer; (B and C) manganese-catalyzed C–H silylat...
Scheme 25: (A and B) Fe-based small molecule catalyst applied for selective aliphatic C–H oxidations; (C) late...
Scheme 26: (A) Examples of naturally occurring gracilioethers; (B) the first total synthesis of gracilioether ...
Scheme 27: (A and B) Selective aliphatic C–H oxidation of amino acids; (C) late-stage modification of proline-...
Scheme 28: (A) Examples of Illicium sesquiterpenes; (B) first chemical synthesis of (+)-pseudoanisatin (80) in...
Scheme 29: (A and B) Fe-catalyzed deuteration; (C) late-stage modification of pharmaceuticals.
Scheme 30: (A and B) Biomimetic Fe-catalyzed aerobic oxidation of methylarenes to benzaldehydes (PMHS, polymet...
Scheme 31: (A) Known tetrahydroquinolines with potential biological activities; (B and C) redox-selective Fe c...
Scheme 32: (A) Known drugs containing a benzofuran unit; (B and C) Fe/Cu-catalyzed tandem O-arylation to acces...
Scheme 33: (A) Known azaindolines that act as M4 muscarinic acetylcholine receptor agonists; (B and C) intramo...
Scheme 34: (A) Known indolinones with anticholinesterase activity; (B and C) oxidative C(sp3)–H cross coupling...
Scheme 35: (A and B) Cobalt-catalyzed C–H alkenylation of C-3-peptide-containing indoles; (C) derivatization b...
Scheme 36: (A) Cobalt-Cp*-catalyzed C–H methylation of known drugs; (B and C) scope of the o-methylated deriva...
Scheme 37: (A) Known lasalocid A analogues; (B and C) three-component cobalt-catalyzed C–H bond addition; (D) ...
Scheme 38: (A and B) Cobalt-catalyzed C(sp2)–H amidation of thiostrepton.
Scheme 39: (A) Known 4H-benzo[d][1,3]oxazin-4-one derivatives with hypolipidemic activity; (B and C) cobalt-ca...
Scheme 40: (A and B) Cobalt-catalyzed C–H arylation of pyrrole derivatives; (C) application for the synthesis ...
Scheme 41: (A) Known 2-phenoxypyridine derivatives with potent herbicidal activity; (B and C) cobalt-catalyzed...
Scheme 42: (A) Natural cinnamic acid derivatives; (B and C) cobalt-catalyzed C–H carboxylation of terminal alk...
Scheme 43: (A and B) Cobalt-catalyzed C–H borylation; (C) application to the synthesis of flurbiprofen.
Scheme 44: (A) Benzothiazoles known to present anticonvulsant activities; (B and C) cobalt/ruthenium-catalyzed...
Scheme 45: (A and B) Cobalt-catalyzed oxygenation of methylene groups towards ketone synthesis; (C) synthesis ...
Scheme 46: (A) Known anticancer tetralone derivatives; (B and C) cobalt-catalyzed C–H difluoroalkylation of ar...
Scheme 47: (A and B) Cobalt-catalyzed C–H thiolation; (C) application in the synthesis of quetiapine (153).
Scheme 48: (A) Known benzoxazole derivatives with anticancer, antifungal, and antibacterial activities; (B and...
Scheme 49: (A and B) Cobalt-catalyzed C–H carbonylation of naphthylamides; (C) BET inhibitors 158 and 159 tota...
Scheme 50: (A) Known bioactive pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives; (B and C) cobalt-catalyzed C–H ...
Scheme 51: (A) Known antibacterial cyclic sulfonamides; (B and C) cobalt-catalyzed C–H amination of propargyli...
Scheme 52: (A and B) Cobalt-catalyzed intramolecular 1,5-C(sp3)–H amination; (C) late-stage functionalization ...
Scheme 53: (A and B) Cobalt-catalyzed C–H/C–H cross-coupling between benzamides and oximes; (C) late-state syn...
Scheme 54: (A) Known anticancer natural isoquinoline derivatives; (B and C) cobalt-catalyzed C(sp2)–H annulati...
Scheme 55: (A) Enantioselective intramolecular nickel-catalyzed C–H activation; (B) bioactive obtained motifs;...
Scheme 56: (A and B) Nickel-catalyzed α-C(sp3)–H arylation of ketones; (C) application of the method using kno...
Scheme 57: (A and B) Nickel-catalyzed C(sp3)–H acylation of pyrrolidine derivatives; (C) exploring the use of ...
Scheme 58: (A) Nickel-catalyzed C(sp3)–H arylation of dioxolane; (B) library of products obtained from biologi...
Scheme 59: (A) Intramolecular enantioselective nickel-catalyzed C–H cycloalkylation; (B) product examples, inc...
Scheme 60: (A and B) Nickel-catalyzed C–H deoxy-arylation of azole derivatives; (C) late-stage functionalizati...
Scheme 61: (A and B) Nickel-catalyzed decarbonylative C–H arylation of azole derivatives; (C) application of t...
Scheme 62: (A and B) Another important example of nickel-catalyzed C–H arylation of azole derivatives; (C) app...
Scheme 63: (A and B) Another notable example of a nickel-catalyzed C–H arylation of azole derivatives; (C) lat...
Scheme 64: (A and B) Nickel-based metalorganic framework (MOF-74-Ni)-catalyzed C–H arylation of azole derivati...
Scheme 65: (A) Known commercially available benzothiophene-based drugs; (B and C) nickel-catalyzed C–H arylati...
Scheme 66: (A) Known natural tetrahydrofuran-containing substances; (B and C) nickel-catalyzed photoredox C(sp3...
Scheme 67: (A and B) Another notable example of a nickel-catalyzed photoredox C(sp3)–H alkylation/arylation; (...
Scheme 68: (A) Electrochemical/nickel-catalyzed C–H alkoxylation; (B) achieved scope, including three using na...
Scheme 69: (A) Enantioselective photoredox/nickel catalyzed C(sp3)–H arylation; (B) achieved scope, including ...
Scheme 70: (A) Known commercially available trifluoromethylated drugs; (B and C) nickel-catalyzed C–H trifluor...
Scheme 71: (A and B) Stereoselective nickel-catalyzed C–H difluoroalkylation; (C) late-stage functionalization...
Scheme 72: (A) Cu-mediated ortho-amination of oxalamides; (B) achieved scope, including derivatives obtained f...
Scheme 73: (A) Electro-oxidative copper-mediated amination of 8-aminoquinoline-derived amides; (B) achieved sc...
Scheme 74: (A and B) Cu(I)-mediated C–H amination with oximes; (C) derivatization using telmisartan (241) as s...
Scheme 75: (A and B) Cu-mediated amination of aryl amides using ammonia; (C) late-stage modification of proben...
Scheme 76: (A and B) Synthesis of purine nucleoside analogues using copper-mediated C(sp2)–H activation.
Scheme 77: (A) Copper-mediated annulation of acrylamide; (B) achieved scope, including the synthesis of the co...
Scheme 78: (A) Known bioactive compounds containing a naphthyl aryl ether motif; (B and C) copper-mediated eth...
Scheme 79: (A and B) Cu-mediated alkylation of N-oxide-heteroarenes; (C) late-stage modification.
Scheme 80: (A) Cu-mediated cross-dehydrogenative coupling of polyfluoroarenes and alkanes; (B) scope from know...
Scheme 81: (A) Known anticancer acrylonitrile compounds; (B and C) Copper-mediated cyanation of unactivated al...
Scheme 82: (A) Cu-mediated radiofluorination of 8-aminoquinoline-derived aryl amides; (B) achieved scope, incl...
Scheme 83: (A) Examples of natural β-carbolines; (B and C) an example of a zinc-catalyzed C–H functionalizatio...
Scheme 84: (A) Examples of anticancer α-aminophosphonic acid derivatives; (B and C) an example of a zinc-catal...
Beilstein J. Org. Chem. 2021, 17, 1453–1463, doi:10.3762/bjoc.17.101
Graphical Abstract
Figure 1: Selected examples of compounds containing the γ-carboline core.
Scheme 1: The synthetic strategy of present work in comparison with previous reports.
Scheme 2: Series of synthesized 1-indolyl-3,5,8-substituted γ-carboline 3aa–ac, 3ba-ea and 1-indolyl-1,2-dihy...
Figure 2: Single-crystal XRD structure of 3ac (CCDC: 1897787).
Scheme 3: Plausible mechanism for the formation of 1,2-dihydro-γ-carboline derivative 3ga and 1-indolyl-3,5,8...
Figure 3: UV–vis absorption (left side) and emission (right side) spectra of 3ac measured in different solven...
Figure 4: Fluorescence decay profile of 3ac in DMSO (left side; λex 360 nm) and 10−5 M solutions of compound ...
Figure 5: Dose–response curves for (A) γ-carbolines 3ac, 3bc, 3ca, 3ga in the breast cancer cell line, MCF7 a...
Figure 6: Dose–response curve of γ-carbolines 3ac, 3bc, 3ca, 3ga in macrophage cell line, RAW264.7.
Figure 7: Laser scanning confocal microscopy studies (λex = 405 nm; collection range = 420–470 nm) for uptake...
Beilstein J. Org. Chem. 2021, 17, 1096–1140, doi:10.3762/bjoc.17.86
Graphical Abstract
Scheme 1: General strategy for the enantioselective synthesis of N-containing heterocycles from N-tert-butane...
Scheme 2: Methodologies for condensation of aldehydes and ketones with tert-butanesulfinamides (1).
Scheme 3: Transition models for cis-aziridines and trans-aziridines.
Scheme 4: Mechanism for the reduction of N-tert-butanesulfinyl imines.
Scheme 5: Transition models for the addition of organomagnesium and organolithium compounds to N-tert-butanes...
Scheme 6: Synthesis of 2,2-dibromoaziridines 15 from aldimines 14 and bromoform, and proposed non-chelation-c...
Scheme 7: Diastereoselective synthesis of aziridines from tert-butanesulfinyl imines.
Scheme 8: Synthesis of vinylaziridines 22 from aldimines 14 and 1,3-dibromopropene 23, and proposed chelation...
Scheme 9: Synthesis of vinylaziridines 27 from aldimines 14 and α-bromoesters 26, and proposed transition sta...
Scheme 10: Synthesis of 2-chloroaziridines 28 from aldimines 14 and dichloromethane, and proposed transition s...
Scheme 11: Synthesis of cis-vinylaziridines 30 and 31 from aldimines 14 and bromomethylbutenolide 29.
Scheme 12: Synthesis of 2-chloro-2-aroylaziridines 36 and 32 from aldimines 14, arylnitriles 34, and silyldich...
Scheme 13: Synthesis of trifluoromethylaziridines 39 and proposed transition state of the aziridination.
Scheme 14: Synthesis of aziridines 42 and proposed state transition.
Scheme 15: Synthesis of 1-substituted 2-azaspiro[3.3]heptanes, 1-phenyl-2-azaspiro[3.4]octane and 1-phenyl-2-a...
Scheme 16: Synthesis of 1-substituted 2,6-diazaspiro[3.3]heptanes 48 from chiral imines 14 and 1-Boc-azetidine...
Scheme 17: Synthesis of β-lactams 52 from chiral imines 14 and dimethyl malonate (49).
Scheme 18: Synthesis of spiro-β-lactam 57 from chiral (RS)-N-tert-butanesulfinyl isatin ketimine 53 and ethyl ...
Scheme 19: Synthesis of β-lactam 60, a precursor of (−)-batzelladine D (61) and (−)-13-epi-batzelladine D (62)...
Scheme 20: Rhodium-catalyzed asymmetric synthesis of 3-substituted pyrrolidines 66 from chiral imine (RS)-63 a...
Scheme 21: Asymmetric synthesis of 1,3-disubstituted isoindolines 69 and 70 from chiral imine 67.
Scheme 22: Asymmetric synthesis of cis-2,5-disubstituted pyrrolidines 73 from chiral imine (RS)-71.
Scheme 23: Asymmetric synthesis of 3-hydroxy-5-substituted pyrrolidin-2-ones 77 from chiral imine (RS)-74.
Scheme 24: Asymmetric synthesis of 4-hydroxy-5-substituted pyrrolidin-2-ones 80 from chiral imines 79.
Scheme 25: Asymmetric synthesis of 3-pyrrolines 82 from chiral imines 14 and ethyl 4-bromocrotonate (81).
Scheme 26: Asymmetric synthesis of γ-amino esters 84, and tetramic acid derivative 86 from chiral imines (RS)-...
Scheme 27: Asymmetric synthesis of α-methylene-γ-butyrolactams 90 from chiral imines (Z,SS)-87 and ethyl 2-bro...
Scheme 28: Asymmetric synthesis of methylenepyrrolidines 92 from chiral imines (RS)-14 and 2-(trimethysilylmet...
Scheme 29: Synthesis of dibenzoazaspirodecanes from cyclic N-tert-butanesulfinyl imines.
Scheme 30: Stereoselective synthesis of cyclopenta[c]proline derivatives 103 from β,γ-unsaturated α-amino acid...
Scheme 31: Stereoselective synthesis of alkaloids (−)-angustureine (107) and (−)-cuspareine (108).
Scheme 32: Stereoselective synthesis of alkaloids (−)-pelletierine (112) and (+)-coniine (117).
Scheme 33: Synthesis of piperidine alkaloids (+)-dihydropinidine (122a), (+)-isosolenopsin (122b) and (+)-isos...
Scheme 34: Stereoselective synthesis of the alkaloids(+)-sedamine (125) from chiral imine (SS)-119.
Scheme 35: Stereoselective synthesis of trans-5-hydroxy-6-substituted-2-piperidinones 127 and 129 from chiral ...
Scheme 36: Stereoselective synthesis of trans-5-hydroxy-6-substituted ethanone-2-piperidinones 132 from chiral...
Scheme 37: Stereoselective synthesis of trans-3-benzyl-5-hydroxy-6-substituted-2-piperidinones 136 from chiral...
Scheme 38: Stereoselective synthesis of trans-5-hydroxy-6-substituted 2-piperidinones 139 from chiral imine 138...
Scheme 39: Stereoselective synthesis of ʟ-hydroxypipecolic acid 145 from chiral imine 144.
Scheme 40: Synthesis of 1-substituted isoquinolones 147, 149 and 151.
Scheme 41: Stereoselective synthesis of 3-substituted dihydrobenzo[de]isoquinolinones 154.
Scheme 42: Enantioselective synthesis of alkaloids (S)-1-benzyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (...
Scheme 43: Enantioselective synthesis of alkaloids (−)-cermizine B (171) and (+)-serratezomine E (172) develop...
Scheme 44: Stereoselective synthesis of (+)-isosolepnosin (177) and (+)-solepnosin (178) from homoallylamine d...
Scheme 45: Stereoselective synthesis of tetrahydroquinoline derivatives 184, 185 and 187 from chiral imines (RS...
Scheme 46: Stereoselective synthesis of pyridobenzofuran and pyridoindole derivatives 193 from homopropargylam...
Scheme 47: Stereoselective synthesis of 2-substituted 1,2,5,6-tetrahydropyridines 196 from chiral imines (RS)-...
Scheme 48: Stereoselective synthesis of 2-substituted trans-2,6-disubstituted piperidine 199 from chiral imine...
Scheme 49: Stereoselective synthesis of cis-2,6-disubstituted piperidines 200, and alkaloid (+)-241D, from chi...
Scheme 50: Stereoselective synthesis of 6-substituted piperidines-2,5-diones 206 and 1,7-diazaspiro[4.5]decane...
Scheme 51: Stereoselective synthesis of spirocyclic oxindoles 210 from chiral imines (RS)-53.
Scheme 52: Stereoselective synthesis of azaspiro compound 213 from chiral imine 211.
Scheme 53: Stereoselective synthesis of tetrahydroisoquinoline derivatives from chiral imines (RS)-214.
Scheme 54: Stereoselective synthesis of (−)-crispine A 223 from chiral imine (RS)-214.
Scheme 55: Synthesis of (−)-harmicine (228) using tert-butanesulfinamide through haloamide cyclization.
Scheme 56: Stereoselective synthesis of tetraponerines T1–T8.
Scheme 57: Stereoselective synthesis of phenanthroindolizidines 246a and (−)-tylophorine (246b), and phenanthr...
Scheme 58: Stereoselective synthesis of indoline, tetrahydroquinoline and tetrahydrobenzazepine derivatives 253...
Scheme 59: Stereoselective synthesis of (+)-epohelmin A (258) and (+)-epohelmin B (260) from aldimine (RS)-79.
Scheme 60: Stereoselective synthesis of (−)-epiquinamide (266) from chiral aldimine (SS)-261.
Scheme 61: Synthesis synthesis of (–)-hippodamine (273) and (+)-epi-hippodamine (272) using chiral sulfinyl am...
Scheme 62: Stereoselective synthesis of (+)-grandisine D (279) and (+)-amabiline (283).
Scheme 63: Stereoselective synthesis of (−)-epiquinamide (266) and (+)-swaisonine (291) from aldimine (SS)-126....
Scheme 64: Stereoselective synthesis of (+)-C(9a)-epi-epiquinamide (294).
Scheme 65: Stereoselective synthesis of (+)-lasubine II (298) from chiral aldimine (SS)-109.
Scheme 66: Stereoselective synthesis of (−)-epimyrtine (300a) and (−)-lasubine II (ent-302) from β-amino keton...
Scheme 67: Stereoselective synthesis of (−)-tabersonine (310), (−)-vincadifformine (311), and (−)-aspidospermi...
Scheme 68: Stereoselective synthesis of (+)-epohelmin A (258) and (+)-epohelmin B (260) from aldehyde 313 and ...
Scheme 69: Total synthesis of (+)-lysergic acid (323) from N-tert-butanesulfinamide (RS)-1.
Beilstein J. Org. Chem. 2021, 17, 730–736, doi:10.3762/bjoc.17.62
Graphical Abstract
Figure 1: Natural products possessing the pyrrolo[2,3-c]quinoline skeleton.
Scheme 1: Total synthesis of marinoquinolines and the failure of the introduction of a tetrahydroquinoline mo...
Scheme 2: Retrosynthetic analysis of the pyrrolo[2,3-c]quinoline ring construction.
Scheme 3: Synthesis of N-substituted 4-aminopyrrolo[3,2-c]quinoline 18.
Scheme 4: Synthesis of the tetrahydroquinoline moiety through cycloamination.
Scheme 5: Synthesis of trigonoine B (1).
Beilstein J. Org. Chem. 2021, 17, 203–209, doi:10.3762/bjoc.17.20
Graphical Abstract
Scheme 1: Flow generation and transformation of 2H-azirines.
Scheme 2: Flow synthesis of 2H-azirines from vinyl azides. aThe solution of vinyl azide was re-introduced twi...
Scheme 3: Mixed flow-batch approach for the preparation of functionalized NH-aziridines from vinyl azides.
Beilstein J. Org. Chem. 2020, 16, 2073–2079, doi:10.3762/bjoc.16.174
Graphical Abstract
Figure 1: Pharmacologically active nonracemic phosphonates with heterocyclic moieties.
Figure 2: Starting nonracemic 4-nitro-2-oxophosphonates.
Scheme 1: Intermolecular N-methylation of reduction product 7.
Scheme 2: Synthesis of pyrrolidinyl phosphonic acids 11a–d.
Figure 3: ORTEP diagram of (2R,3R,4S)-10a.
Scheme 3: Synthesis of tetrahydropyranylphosphonates 13a–f via diastereoselective Henry/acetalyzation reactio...
Figure 4: ORTEP diagram of (2S,3R,4S,5S,6R)-13b.
Scheme 4: Synthesis of (3,4-dihydro-2H-pyran-5-yl)phosphonate 14.
Beilstein J. Org. Chem. 2020, 16, 1740–1753, doi:10.3762/bjoc.16.146
Graphical Abstract
Figure 1: Representative examples of some commercial drugs and biologically active alkaloids.
Scheme 1: Synthesis of β-carboline-linked 2-nitrochalcones.
Scheme 2: Synthesis of β-carboline-linked benzothiophenone frameworks.
Scheme 3: Comparison of outcome of one-pot vs two-pot approach.
Scheme 4: One-pot synthesis of β-carboline C-1-tethered benzothiophenone derivatives.
Scheme 5: One-pot synthesis of β-carboline C-3-linked benzothiophenone derivatives.
Scheme 6: One-pot synthesis of β-carboline-linked benzothiophene derivative 6C.
Scheme 7: Control experiment in the presence of a radical scavenger.
Figure 2: Proposed reaction mechanism.
Figure 3: Fluorescence spectra of 2aA–nA, 2bB, 2hB, and 6C.
Figure 4: Fluorescence spectra of 4aA–gA, and 4eB.
Beilstein J. Org. Chem. 2020, 16, 833–857, doi:10.3762/bjoc.16.76
Graphical Abstract
Scheme 1: Norrish type I and II dissociations.
Scheme 2: Proposed radical pair formation after the photolysis of benzaldehyde (8).
Scheme 3: Aldehydes in the Paterno–Büchi reaction.
Scheme 4: 2,3-Diazabicyclo[2.2.1]hept-2-ene (DBH).
Scheme 5: Dissociation pathways of benzaldehyde.
Scheme 6: Reactions that lead to polarized products detectable by CIDNP.
Scheme 7: MMA (26), DEABP (27), and Michler’s ketone (28).
Scheme 8: Radical intermediates of DEABP.
Scheme 9: Photoinitiated polymerization of monomeric MMA (26) using the quinoxalines 32 and benzaldehyde (8).
Scheme 10: Acetone (4) and formaldehyde (35) as photografting initiators.
Scheme 11: Photografting by employing acetaldehyde (36) as the photoinitiator.
Scheme 12: Proposed photolysis mechanism for aliphatic ketones 44 and formaldehyde (35).
Scheme 13: Initiator 50, reductant 51, and benzaldehyde derivatives 52–54 for the polymerization of the methac...
Scheme 14: Proposed mechanism of the photomediated atom transfer radical polymerization employing the benzalde...
Scheme 15: cis/trans isomerization employing triplet states of photosensitizers.
Scheme 16: Salicylaldehyde (68) forms an internal hydrogen bond.
Scheme 17: Olefin isomerization via energy transfer from a carbonyl compound.
Scheme 18: Mechanistic pathways for the Paterno–Büchi reaction.
Scheme 19: Isomeric oxetanes formed after photochemical addition of aryl aldehydes to 2-butenes.
Scheme 20: Rotation of the C3–C4 bond of the biradical intermediate may lead to all four conformations.
Scheme 21: Photolysis products of benzaldehyde (8) in different solvents. a) In benzene or ethanol. b) In hex-...
Scheme 22: N-tert-Butylbenzamide formation proceeds via a benzoyl radical.
Scheme 23: Photochemical pinacol coupling.
Scheme 24: Photochemical ATRA catalyzed by 4-anisaldehyde (52).
Scheme 25: Proposed triplet sensitization mechanism of the ATRA reaction in the presence of 4-anisaldehyde (52...
Scheme 26: Benzaldehyde-mediated photoredox CDC reaction: compatible amides and ethers.
Scheme 27: Photoredox cross-dehydrogenative coupling (CDC) conditions and proposed reaction mechanism.
Scheme 28: Optimized conditions for the photoredox merger reaction.
Scheme 29: Proposed mechanism for the C(sp3)–H alkylation/arylation of ethers.
Scheme 30: Substrate scope for the photochemical alkylation of ethers.
Scheme 31: C(sp3)–H Functionalization of N-containing molecules.
Scheme 32: Substrate scope for the photochemical alkylation of N-containing molecules.
Scheme 33: Additional products yielded by the photochemical alkylation reaction of N-containing molecules.
Scheme 34: C(sp3)–H functionalization of thioethers.
Scheme 35: Proposed mechanism for the C(sp3)–H alkylation/arylation of N-containing molecules and thioethers.
Scheme 36: Hydroacylation using 4-cyanobenzaldehyde (53) as the photoinitiator.
Scheme 37: Selectivity for the formation of the α,α-disubstituted aldehydes.
Scheme 38: Substrate scope for the photochemical addition of aldehydes to Michael acceptors.
Scheme 39: Proposed mechanism for the hydroacylation of Michael acceptors using 4-cyanobenzaldehyde (53) as th...
Scheme 40: Catalytic arylation of aromatic aldehydes by aryl bromides in which the reaction product acts as th...
Scheme 41: Proposed mechanism for the catalytic arylation of benzaldehydes by aryl bromides in which the react...
Scheme 42: Functionalization of the chiral cyclobutanes 180.
Scheme 43: Optimized reaction conditions and proposed mechanism for the sulfonylcyanation of cyclobutenes.
Beilstein J. Org. Chem. 2020, 16, 738–755, doi:10.3762/bjoc.16.68
Graphical Abstract
Scheme 1: Intramolecular (A) and intermolecular (B) enyne metathesis reactions.
Scheme 2: Ene–yne and yne–ene mechanisms for intramolecular enyne metathesis reactions.
Scheme 3: Metallacarbene mechanism in intermolecular enyne metathesis.
Scheme 4: The Oguri strategy for accessing artemisinin analogs 1a–c through enyne metathesis.
Scheme 5: Access to the tetracyclic core of nanolobatolide (2) via tandem enyne metathesis followed by an Eu(...
Scheme 6: Synthesis of (−)-amphidinolide E (3) using an intermolecular enyne metathesis as the key step.
Scheme 7: Synthesis of amphidinolide K (4) by an enyne metathesis route.
Scheme 8: Trost synthesis of des-epoxy-amphidinolide N (5) [72].
Scheme 9: Enyne metathesis between the propargylic derivative and the allylic alcohol in the synthesis of the...
Scheme 10: Synthetic route to amphidinolide N (6a).
Scheme 11: Synthesis of the stereoisomeric precursors of amphidinolide V (7a and 7b) through alkyne ring-closi...
Scheme 12: Synthesis of the anthramycin precursor 8 from ʟ-methionine by a tandem enyne metathesis–cross metat...
Scheme 13: Synthesis of (−)‐clavukerin A (9) and (−)‐isoclavukerin A (10) by an enyne metathesis route startin...
Scheme 14: Synthesis of (−)-isoguaiene (11) through an enyne metathesis as the key step.
Scheme 15: Synthesis of erogorgiaene (12) by a tandem enyne metathesis/cross metathesis sequence using the sec...
Scheme 16: Synthesis of (−)-galanthamine (13) from isovanilin by an enyne metathesis.
Scheme 17: Application of enyne metathesis for the synthesis of kempene diterpenes 14a–c.
Scheme 18: Synthesis of the alkaloid (+)-lycoflexine (15) through enyne metathesis.
Scheme 19: Synthesis of the AB subunits of manzamine A (16a) and E (16b) by enyne metathesis.
Scheme 20: Jung's synthesis of rhodexin A (17) by enyne metathesis/cross metathesis reactions.
Scheme 21: Total synthesis of (−)-flueggine A (18) and (+)-virosaine B (19) from Weinreb amide by enyne metath...
Scheme 22: Access to virgidivarine (20) and virgiboidine (21) by an enyne metathesis route.
Scheme 23: Enyne metathesis approach to (−)-zenkequinone B (22).
Scheme 24: Access to C-aryl glycoside 23 by an intermolecular enyne metathesis/Diels–Alder cycloaddition.
Scheme 25: Synthesis of spiro-C-aryl glycoside 24 by a tandem intramolecular enyne metathesis/Diels–Alder reac...
Scheme 26: Pathways to (−)-exiguolide (25) by Trost’s Ru-catalyzed enyne cross-coupling and cross-metathesis [94].
Beilstein J. Org. Chem. 2019, 15, 2968–2981, doi:10.3762/bjoc.15.293
Graphical Abstract
Figure 1: Chemical structures of the isolated compounds 1–6.
Figure 2: Experimental and TDDFT-calculated ECD spectra of compounds 1 (A), 2 (B), and 3 (C) in MeOH.
Figure 3: A) Selected COSY (bold bonds) and HMBC (red arrows) correlations for compounds 2 and 3. B) Partial ...
Figure 4: Chemical structures of selected, literature-known compounds that are related to this study.
Figure 5: HPLC–UV–vis profiles (200–600 nm) generated from the culture filtrate extracts of several isolates ...
Figure 6: HPLC–UV–vis profiles (200–600 nm) generated from the culture filtrate extracts of several isolates ...
Beilstein J. Org. Chem. 2018, 14, 1508–1528, doi:10.3762/bjoc.14.128
Graphical Abstract
Scheme 1: Strategies to address the issue of sustainability with polyvalent organoiodine reagents.
Scheme 2: Functionalization of ketones and alkenes with IBX.
Scheme 3: Functionalization of pyrroles with DMP.
Scheme 4: Catalytic benzoyloxy-trifluoromethylation reported by Szabó.
Scheme 5: Catalytic benzoyloxy-trifluoromethylation reported by Mideoka.
Scheme 6: Catalytic 1,4-benzoyloxy-trifluoromethylation of dienes.
Scheme 7: Catalytic benzoyloxy-trifluoromethylation of allylamines.
Scheme 8: Catalytic benzoyloxy-trifluoromethylation of enynes.
Scheme 9: Catalytic benzoyloxy-trifluoromethylation of allenes.
Scheme 10: Alkynylation of N-(aryl)imines with EBX for the formation of furans.
Scheme 11: Catalytic benzoyloxy-alkynylation of diazo compounds.
Scheme 12: Catalytic asymmetric benzoyloxy-alkynylation of diazo compounds.
Scheme 13: Catalytic 1,2-benzoyloxy-azidation of alkenes.
Scheme 14: Catalytic 1,2-benzoyloxy-azidation of enamides.
Scheme 15: Catalytic 1,2-benzoyloxy-iodination of alkenes.
Scheme 16: Seminal study with cyclic diaryl-λ3-iodane.
Scheme 17: Synthesis of alkylidenefluorenes from cyclic diaryl-λ3-iodanes.
Scheme 18: Synthesis of alkyne-substituted alkylidenefluorenes.
Scheme 19: Synthesis of phenanthrenes from cyclic diaryl-λ3-iodanes.
Scheme 20: Synthesis of dibenzocarbazoles from cyclic diaryl-λ3-iodanes.
Scheme 21: Synthesis of triazolophenantridines from cyclic diaryl-λ3-iodanes.
Scheme 22: Synthesis of functionalized benzoxazoles from cyclic diaryl-λ3-iodanes.
Scheme 23: Sequential difunctionalization of cyclic diaryl-λ3-iodanes.
Scheme 24: Double Suzuki–Miyaura coupling reaction of cyclic diaryl-λ3-iodanes.
Scheme 25: Synthesis of a δ-carboline from cyclic diaryl-λ3-iodane.
Scheme 26: Synthesis of N-(aryl)carbazoles from cyclic diaryl-λ3-iodanes.
Scheme 27: Synthesis of carbazoles from cyclic diaryl-λ3-iodanes.
Scheme 28: Synthesis of carbazoles and acridines from cyclic diaryl-λ3-iodanes.
Scheme 29: Synthesis of dibenzothiophenes from cyclic diaryl-λ3-iodanes.
Scheme 30: Synthesis of various sulfur heterocycles from cyclic diaryl-λ3-iodanes.
Scheme 31: Synthesis of dibenzothioheterocycles from cyclic diaryl-λ3-iodanes.
Scheme 32: Synthesis of dibenzosulfides and dibenzoselenides from cyclic diaryl-λ3-iodanes.
Scheme 33: Synthesis of dibenzosulfones from cyclic diaryl-λ3-iodanes.
Scheme 34: Seminal study with linear diaryl-λ3-iodanes.
Scheme 35: N-Arylation of benzotriazole with symmetrical diaryl-λ3-iodanes.
Scheme 36: Tandem catalytic C–H/N–H arylation of indoles with diaryl-λ3-iodanes.
Scheme 37: Tandem N-arylation/C(sp2)–H arylation with diaryl-λ3-iodanes.
Scheme 38: Catalytic intermolecular diarylation of anilines with diaryl-λ3-iodanes.
Scheme 39: Catalytic synthesis of diarylsulfides with diaryl-λ3-iodanes.
Scheme 40: α-Arylation of enolates using [bis(trifluoroacetoxy)iodo]arenes.
Scheme 41: Mechanism of the α-arylation using [bis(trifluoroacetoxy)iodo]arene.
Scheme 42: Catalytic nitrene additions mediated by [bis(acyloxy)iodo]arenes.
Scheme 43: Tandem of C(sp3)–H amination/sila-Sonogashira–Hagihara coupling.
Scheme 44: Tandem reaction using a λ3-iodane as an oxidant, a substrate and a coupling partner.
Scheme 45: Synthesis of 1,2-diarylated acrylamidines with ArI(OAc)2.
Beilstein J. Org. Chem. 2018, 14, 560–575, doi:10.3762/bjoc.14.43
Graphical Abstract
Scheme 1: Formation of amidoalkylnaphthols 4 via o-QM intermediate 3.
Scheme 2: Asymmetric syntheses of triarylmethanes starting from diarylmethylamines.
Scheme 3: Proposed mechanism for the formation of 2,2-dialkyl-3-dialkylamino-2,3-dihydro-1H-naphtho[2,1-b]pyr...
Scheme 4: Cycloadditions of isoflavonoid-derived o-QMs and various dienophiles.
Scheme 5: [4 + 2] Cycloaddition reactions between aminonaphthols and cyclic amines.
Scheme 6: Brønsted acid-catalysed reaction between aza-o-QMs and 2- or 3-substituted indoles.
Scheme 7: Formation of 3-(α,α-diarylmethyl)indoles 52 in different synthetic pathways.
Scheme 8: Alkylation of o-QMs with N-, O- or S-nucleophiles.
Scheme 9: Formation of DNA linkers and o-QM mediated polymers.
Beilstein J. Org. Chem. 2018, 14, 282–308, doi:10.3762/bjoc.14.18
Graphical Abstract
Figure 1: Radiative deactivation pathways existing in fluorescent, phosphorescent and TADF materials.
Figure 2: Boron-containing TADF emitters B1–B10.
Figure 3: Diphenylsulfone-based TADF emitters D1–D7.
Figure 4: Triazine-based TADF emitters T1–T3, T5–T7 and azasiline derivatives T3 and T4.
Figure 5: Triazine-based TADF emitters T8, T9, T11–T14 and carbazole derivative T10.
Figure 6: Triazine-based TADF emitters T15–T19.
Figure 7: Triazine- and pyrimidine-based TADF emitters T20–T26.
Figure 8: Pyrimidine-based TADF emitters T27–T30.
Figure 9: Triazine-based TADF polymers T31–T32.
Figure 10: Phenoxaphosphine oxide and phenoxathiin dioxide-based TADF emitters P1 and P2.
Figure 11: CN-Substituted pyridine and pyrimidine derivatives CN-P1–CN-P8.
Figure 12: CN-Substituted pyridine derivatives CN-P9 and CN-P10.
Figure 13: Phosphine oxide-based TADF blue emitters PO-1–PO-3.
Figure 14: Phosphine oxide-based TADF blue emitters PO-4–PO-9.
Figure 15: Benzonitrile-based emitters BN-1–BN-5.
Figure 16: Benzonitrile-based emitters BN-6–BN-11.
Figure 17: Benzoylpyridine-carbazole hybrid emitters BP-1–BP-6.
Figure 18: Benzoylpyridine-carbazole hybrid emitters BP-7–BP-10.
Figure 19: Triazole-based emitters Trz-1 and Trz-2.
Figure 20: Triarylamine-based emitters TPA-1–TPA-3.
Figure 21: Distribution of the CIE coordinates of ca. 90 blue TADF emitters listed in this review.
Beilstein J. Org. Chem. 2017, 13, 1670–1692, doi:10.3762/bjoc.13.162
Graphical Abstract
Figure 1: Representative bioactive heterocycles.
Scheme 1: The concept of oxidative dehydrogenation.
Scheme 2: IBX-mediated oxidative dehydrogenation of various heterocycles [31-34].
Scheme 3: Potential mechanism of IBX-mediated oxidative dehydrogenation of N-heterocycles [31-34].
Scheme 4: IBX-mediated room temperature one-pot condensation–oxidative dehydrogenation of o-aminobenzylamines....
Scheme 5: Anhydrous cerium chloride-catalyzed, IBX-mediated oxidative dehydrogenation of various heterocycles...
Scheme 6: Oxidative dehydrogenation of quinazolinones with I2 and DDQ [37-40].
Scheme 7: DDQ-mediated oxidative dehydrogenation of thiazolidines and oxazolidines.
Scheme 8: Oxone-mediated oxidative dehydrogenation of intermediates from o-phenylenediamine and o-aminobenzyl...
Scheme 9: Transition metal-free oxidative cross-dehydrogenative coupling.
Scheme 10: NaOCl-mediated oxidative dehydrogenation.
Scheme 11: NBS-mediated oxidative dehydrogenation of tetrahydro-β-carbolines.
Scheme 12: One-pot synthesis of various methyl(hetero)arenes from o-aminobenzamide in presence of di-tert-buty...
Scheme 13: Oxidative dehydrogenation of 1, 4-DHPs.
Scheme 14: Synthesis of quinazolines in the presence of MnO2.
Scheme 15: Selenium dioxide and potassium dichromate-mediated oxidative dehydrogenation of tetrahydro-β-carbol...
Scheme 16: Synthesis of substituted benzazoles in the presence of barium permanganate.
Scheme 17: Oxidative dehydrogenation with phenanthroline-based catalysts. PPTS = pyridinium p-toluenesulfonic ...
Scheme 18: Oxidative dehydrogenation with Flavin mimics.
Scheme 19: o-Quinone based bioinspired catalysts for the synthesis of dihydroisoquinolines.
Scheme 20: Cobalt-catalyzed aerobic dehydrogenation of Hantzch 1,4-DHPs and pyrazolines.
Scheme 21: Mechanism of cobalt-catalyzed aerobic dehydrogenation of Hantzch 1,4-DHPs.
Scheme 22: DABCO and TEMPO-catalyzed aerobic oxidative dehydrogenation of quinazolines and 4H-3,1-benzoxazines....
Scheme 23: Putative mechanism for Cu(I)–DABCO–TEMPO catalyzed aerobic oxidative dehydrogenation of tetrahydroq...
Scheme 24: Potassium triphosphate modified Pd/C catalysts for the oxidative dehydrogenation of tetrahydroisoqu...
Scheme 25: Ruthenium-catalyzed polycyclic heteroarenes.
Scheme 26: Plausible mechanism of the ruthenium-catalyzed dehydrogenation.
Scheme 27: Bi-metallic platinum/iridium alloyed nanoclusters and 5,5’,6,6’-tetrahydroxy-3,3,3’,3’-tetramethyl-...
Scheme 28: Magnesium iodide-catalyzed synthesis of quinazolines.
Scheme 29: Ferrous chloride-catalyzed aerobic dehydrogenation of 1,2,3,4-tetrahydroquinolines.
Scheme 30: Cu(I)-catalyzed oxidative aromatization of indoles.
Scheme 31: Putative mechanism of the transformation.
Scheme 32: Oxidative dehydrogenation of pyrimidinones and pyrimidines.
Scheme 33: Putative mechanisms (radical and metal-catalyzed) of the transformation.
Scheme 34: Ferric chloride-catalyzed, TBHP-oxidized synthesis of substituted quinazolinones and arylquinazolin...
Scheme 35: Iridium-catalyzed oxidative dehydrogenation of quinolines.
Scheme 36: Microwave-assisted synthesis of β-carboline with a catalytic amount of Pd/C in lithium carbonate at...
Scheme 37: 4-Methoxy-TEMPO-catalyzed aerobic oxidative synthesis of 2-substituted benzazoles.
Scheme 38: Plausible mechanism of the 4-methoxy-TEMPO-catalyzed transformation.
Scheme 39: One-pot synthesis of 2-arylquinazolines, catalyzed by 4-hydroxy-TEMPO.
Scheme 40: Oxidative dehydrogenation – a key step in the synthesis of AZD8926.
Scheme 41: Catalytic oxidative dehydrogenation of tetrahydroquinolines to afford bioactive molecules.
Scheme 42: Iodobenzene diacetate-mediated synthesis of β-carboline natural products.
Beilstein J. Org. Chem. 2017, 13, 428–440, doi:10.3762/bjoc.13.46
Graphical Abstract
Figure 1: Selected active pyrazinoisoquinolines, 2-oxopiperazines and aldose reductase inhibitors (ALR2).
Scheme 1: Comparison of previous reports with present work for piperazine-2,6-dione synthesis.
Scheme 2: Coupling of N-benzenesulfonyliminodiacetic acid with primary amines using CDI/DMAP.
Scheme 3: Formation of ene-diamides 9a–g and pyrazinones 10a–f.
Scheme 4: Mechanism for the formation of substituted pyrazinones.
Figure 2: HRMS spectra of aliquot generated from cyclization reaction of 7c.
Figure 3: ORTEP diagrams of compound 9b and 10a.
Scheme 5: Synthesis of 3-phenylpyrazinone.
Scheme 6: Synthesis of 4-N-benzyl-1-N-(aryl/heteroarylethyl)piperazine-2,6-dione.
Scheme 7: Cyclization of pyrazinoisoquinolines.
Scheme 8: Synthesis of the drug praziquantel 1.
Beilstein J. Org. Chem. 2016, 12, 462–495, doi:10.3762/bjoc.12.48
Graphical Abstract
Scheme 1: Activation of carbonyl compounds via enamine and iminium intermediates [2].
Scheme 2: Electronic and steric interactions present in enamine activation mode [2].
Scheme 3: Electrophilic activation of carbonyl compounds by a thiourea moiety.
Scheme 4: Asymmetric synthesis of dihydro-2H-pyran-6-carboxylate 3 using organocatalyst 4 [16].
Scheme 5: Possible hydrogen-bonding for the reaction of (E)-methyl 2-oxo-4-phenylbut-3-enoate [16].
Scheme 6: Asymmetric desymmetrization of 4,4-cyclohexadienones using the Michael addition reaction with malon...
Scheme 7: The enantioselective synthesis of α,α-disubstituted cycloalkanones using catalyst 11 [18].
Scheme 8: The enantioselective synthesis of indolo- and benzoquinolidine compounds through aza-Diels–Alder re...
Scheme 9: Enantioselective [5 + 2] cycloaddition [20].
Scheme 10: Asymmetric synthesis of oxazine derivatives 26 [21].
Scheme 11: Asymmetric synthesis of bicyclo[3.3.1]nonadienone, core 30 present in (−)-huperzine [22].
Scheme 12: Asymmetric inverse electron-demand Diels-Alder reaction catalyzed by amine-thiourea 34 [23].
Scheme 13: Asymmetric entry to morphan skeletons, catalyzed by amine-thiourea 37 [24].
Scheme 14: Asymmetric transformation of (E)-2-nitroallyl acetate [25].
Scheme 15: Proposed way of activation.
Scheme 16: Asymmetric synthesis of nitrobicyclo[3.2.1]octan-2-one derivatives [26].
Scheme 17: Asymmetric tandem Michael–Henry reaction catalyzed by 50 [27].
Scheme 18: Asymmetric Diels–Alder reactions of 3-vinylindoles 51 [29].
Scheme 19: Proposed transition state and activation mode of the asymmetric Diels–Alder reactions of 3-vinylind...
Scheme 20: Desymmetrization of meso-anhydrides by Chin, Song and co-workers [30].
Scheme 21: Desymmetrization of meso-anhydrides by Connon and co-workers [31].
Scheme 22: Asymmetric intramolecular Michael reaction [32].
Scheme 23: Asymmetric addition of malonate to 3-nitro-2H-chromenes 67 [33].
Scheme 24: Intramolecular desymmetrization through an intramolecular aza-Michael reaction [34].
Scheme 25: Enantioselective synthesis of (−)-mesembrine [34].
Scheme 26: A novel asymmetric Michael–Michael reaction [35].
Scheme 27: Asymmetric three-component reaction catalyzed by Takemoto’s catalyst 77 [46].
Scheme 28: Asymmetric domino Michael–Henry reaction [47].
Scheme 29: Asymmetric domino Michael–Henry reaction [48].
Scheme 30: Enantioselective synthesis of derivatives of 3,4-dihydro-2H-pyran 89 [49].
Scheme 31: Asymmetric addition of α,α-dicyano olefins 90 to 3-nitro-2H-chromenes 91 [50].
Scheme 32: Asymmetric three-component reaction producing 2,6-diazabicyclo[2.2.2]octanones 95 [51].
Scheme 33: Asymmetric double Michael reaction producing substituted chromans 99 [52].
Scheme 34: Enantioselective synthesis of multi-functionalized spiro oxindole dienes 106 [53].
Scheme 35: Organocatalyzed Michael aldol cyclization [54].
Scheme 36: Asymmetric synthesis of dihydrocoumarins [55].
Scheme 37: Asymmetric double Michael reaction en route to tetrasubstituted cyclohexenols [56].
Scheme 38: Asymmetric synthesis of α-trifluoromethyl-dihydropyrans 121 [58].
Scheme 39: Tyrosine-derived tertiary amino-thiourea 123 catalyzed Michael hemiaketalization reaction [59].
Scheme 40: Enantioselective entry to bicyclo[3.2.1]octane unit [60].
Scheme 41: Asymmetric synthesis of spiro[4-cyclohexanone-1,3’-oxindoline] 126 [61].
Scheme 42: Kinetic resolution of 3-nitro-2H-chromene 130 [62].
Scheme 43: Asymmetric synthesis of chromanes 136 [63].
Scheme 44: Wang’s utilization of β-unsaturated α-ketoesters 87 [64,65].
Scheme 45: Asymmetric entry to trifluoromethyl-substituted dihydropyrans 144 [66].
Scheme 46: Phenylalanine-derived thiourea-catalyzed domino Michael hemiaketalization reaction [67].
Scheme 47: Asymmetric synthesis of α-trichloromethyldihydropyrans 149 [68].
Scheme 48: Takemoto’s thiourea-catalyzed domino Michael hemiaketalization reaction [69].
Scheme 49: Asymmetric synthesis of densely substituted cyclohexanes [70].
Scheme 50: Enantioselective synthesis of polysubstituted chromeno [4,3-b]pyrrolidine derivatines 157 [71].
Scheme 51: Enantioselective synthesis of spiro-fused cyclohexanone/5-oxazolone scaffolds 162 [72].
Scheme 52: Utilizing 2-mercaptobenzaldehydes 163 in cascade processes [73,74].
Scheme 53: Proposed transition state of the initial sulfa-Michael step [74].
Scheme 54: Asymmetric thiochroman synthesis via dynamic kinetic resolution [75].
Scheme 55: Enantioselective synthesis of thiochromans [76].
Scheme 56: Enantioselective synthesis of chromans and thiochromans synthesis [77].
Scheme 57: Enantioselective sulfa-Michael aldol reaction en route to spiro compounds [78].
Scheme 58: Enantioselective synthesis of 4-aminobenzo(thio)pyrans 179 [79].
Scheme 59: Asymmetric synthesis of tetrahydroquinolines [80].
Scheme 60: Novel asymmetric Mannich–Michael sequence producing tetrahydroquinolines 186 [81].
Scheme 61: Enantioselective synthesis of biologically interesting chromanes 190 and 191 [82].
Scheme 62: Asymmetric tandem Henry–Michael reaction [83].
Scheme 63: An asymmetric synthesis of substituted cyclohexanes via a dynamic kinetic resolution [84].
Scheme 64: Three component-organocascade initiated by Knoevenagel reaction [85].
Scheme 65: Asymmetric Michael reaction catalyzed by catalysts 57 and 211 [86].
Scheme 66: Proposed mechanism for the asymmetric Michael reaction catalyzed by catalysts 57 and 211 [86].
Scheme 67: Asymmetric facile synthesis of hexasubstituted cyclohexanes [87].
Scheme 68: Dual activation catalytic mechanism [87].
Scheme 69: Asymmetric Michael–Michael/aldol reaction catalyzed by catalysts 57, 219 and 214 [88].
Scheme 70: Asymmetric synthesis of substituted cyclohexane derivatives, using catalysts 57 and 223 [89].
Scheme 71: Asymmetric synthesis of substituted piperidine derivatives, using catalysts 223 and 228 [90].
Scheme 72: Asymmetric synthesis of endo-exo spiro-dihydropyran-oxindole derivatives catalyzed by catalyst 232 [91]....
Scheme 73: Asymmetric synthesis of carbazole spiroxindole derivatives, using catalyst 236 [92].
Scheme 74: Enantioselective formal [2 + 2] cycloaddition of enal 209 with nitroalkene 210, using catalysts 23 ...
Scheme 75: Asymmetric synthesis of polycyclized hydroxylactams derivatives, using catalyst 242 [94].
Scheme 76: Asymmetric synthesis of product 243, using catalyst 246 [95].
Scheme 77: Formation of the α-stereoselective acetals 248 from the corresponding enol ether 247, using catalys...
Scheme 78: Selective glycosidation, catalyzed by Shreiner’s catalyst 23 [97].
Beilstein J. Org. Chem. 2015, 11, 1997–2006, doi:10.3762/bjoc.11.216
Graphical Abstract
Figure 1: Examples of drugs embodying unnatural amino acids.
Figure 2: Examples of biologically active compounds embodying constrained analogues of tryptophan.
Scheme 1: Planned Diels–Alder reactions for the synthesis of tetrahydrocarbazoles as constrained analogues of...
Figure 3: Structure elucidation of diastereoisomeric tetrahydrocarbazoles 3a and 3’a via NMR experiments.
Scheme 2: Synthesis of unprotected tryptophan derivatives 6a–e.
Scheme 3: Plausible reaction mechanism for the cycloaddition reactions of indoles 1a–h with 2 in toluene.
Scheme 4: Cycloaddition reaction of 2-vinylindole 1k and methyl 2-acetamidoacrylate (2).
Beilstein J. Org. Chem. 2015, 11, 1360–1366, doi:10.3762/bjoc.11.146
Graphical Abstract
Figure 1: Naturally occurring β-carbolinones.
Scheme 1: Preparation of starting substrate.
Scheme 2: Synthesis of various β-carbolinone derivatives.
Figure 2: ORTEP diagram of 5h.
Scheme 3: Proposed mechanistic pathway.
Beilstein J. Org. Chem. 2014, 10, 848–857, doi:10.3762/bjoc.10.81
Graphical Abstract
Figure 1: Pyridoisoindole frameworks (highlighted) in bioactive molecules and compounds under present investi...
Scheme 1: Comparison of the retro-synthetic approach for the synthesis of isoindoloquinoline skeleton reporte...
Scheme 2: Mechanistic explanation for regio- and diastereoselectivity leading to (±)-6,6a-dihydroisoindolo[2,...
Figure 2: ORTEP diagrams and 2D structures for the isoindolo[2,1-a]quinolone derivatives 1b, 1h and 2b.
Figure 3: ORTEP diagram and 2D structure of E-2-(2-fluorophenyl)-3-(2-(2-oxopyrrolidin-1-yl)vinyl)isoindolin-...
Scheme 3: Most plausible mechamism for the formation of E-2-(2-substituted-phenyl)-3-(2-(2-oxopyrrolidin-1-yl...
Figure 4: Rotational barrier calculation across N-aryl bond for the N-acyliminium ion intermediates of 1a [A]...
Beilstein J. Org. Chem. 2014, 10, 544–598, doi:10.3762/bjoc.10.50
Graphical Abstract
Scheme 1: The proposed mechanism of the Passerini reaction.
Scheme 2: The PADAM-strategy to α-hydroxy-β-amino amide derivatives 7. An additional oxidation provides α-ket...
Scheme 3: The general accepted Ugi-mechanism.
Scheme 4: Three commonly applied Ugi/cyclization approaches. a) UDC-process, b) UAC-sequence, c) UDAC-combina...
Scheme 5: Ugi reaction that involves the condensation of Armstrong’s convertible isocyanide.
Scheme 6: Mechanism of the U-4C-3CR towards bicyclic β-lactams.
Scheme 7: The Ugi 4C-3CR towards oxabicyclo β-lactams.
Scheme 8: Ugi MCR between an enantiopure monoterpene based β-amino acid, aldehyde and isocyanide resulting in...
Scheme 9: General MCR for β-lactams in water.
Scheme 10: a) Ugi reaction for β-lactam-linked peptidomimetics. b) Varying the β-amino acid resulted in β-lact...
Scheme 11: Ugi-4CR followed by a Pd-catalyzed Sn2 cyclization.
Scheme 12: Ugi-3CR of dipeptide mimics from 2-substituted pyrrolines.
Scheme 13: Joullié–Ugi reaction towards 2,5-disubstituted pyrrolidines.
Scheme 14: Further elaboration of the Ugi-scaffold towards bicyclic systems.
Scheme 15: Dihydroxyproline derivatives from an Ugi reaction.
Scheme 16: Diastereoselective Ugi reaction described by Banfi and co-workers.
Scheme 17: Similar Ugi reaction as in Scheme 16 but with different acids and two chiral isocyanides.
Scheme 18: Highly diastereoselective synthesis of pyrrolidine-dipeptoids via a MAO-N/MCR-procedure.
Scheme 19: MAO-N/MCR-approach towards the hepatitis C drug telaprevir.
Scheme 20: Enantioselective MAO-U-3CR procedure starting from chiral pyrroline 64.
Scheme 21: Synthesis of γ-lactams via an UDC-sequence.
Scheme 22: Utilizing bifunctional groups to provide bicyclic γ-lactam-ketopiperazines.
Scheme 23: The Ugi reaction provided both γ- as δ-lactams depending on which inputs were used.
Scheme 24: The sequential Ugi/RCM with olefinic substrates provided bicyclic lactams.
Scheme 25: a) The structural and dipole similarities of the triazole unit with the amide bond. b) The copper-c...
Scheme 26: The Ugi/Click sequence provided triazole based peptidomimetics.
Scheme 27: The Ugi/Click reaction as described by Nanajdenko.
Scheme 28: The Ugi/Click-approach by Pramitha and Bahulayan.
Scheme 29: The Ugi/Click-combination by Niu et al.
Scheme 30: Triazole linked peptidomimetics obtained from two separate MCRs and a sequential Click reaction.
Scheme 31: Copper-free synthesis of triazoles via two MCRs in one-pot.
Scheme 32: The sequential Ugi/Paal–Knorr reaction to afford pyrazoles.
Scheme 33: An intramolecular Paal–Knorr condensation provided under basic conditions pyrazolones.
Scheme 34: Similar cyclization performed under acidic conditions provided pyrazolones without the trifluoroace...
Scheme 35: The Ugi-4CR towards 2,4-disubstituted thiazoles.
Scheme 36: Solid phase approach towards thiazoles.
Scheme 37: Reaction mechanism of formation of thiazole peptidomimetics containing an additional β-lactam moiet...
Scheme 38: The synthesis of the trisubstituted thiazoles could be either performed via an Ugi reaction with pr...
Scheme 39: Performing the Ugi reaction with DMB-protected isocyanide gave access to either oxazoles or thiazol...
Scheme 40: Ugi/cyclization-approach towards 2,5-disubstituted thiazoles. The Ugi reaction was performed with d...
Scheme 41: Further derivatization of the thiazole scaffold.
Scheme 42: Three-step procedure towards the natural product bacillamide C.
Scheme 43: Ugi-4CR to oxazoles reported by Zhu and co-workers.
Scheme 44: Ugi-based synthesis of oxazole-containing peptidomimetics.
Scheme 45: TMNS3 based Ugi reaction for peptidomimics containing a tetrazole.
Scheme 46: Catalytic cycle of the enantioselective Passerini reaction towards tetrazole-based peptidomimetics.
Scheme 47: Tetrazole-based peptidomimetics via an Ugi reaction and a subsequent sigmatropic rearrangement.
Scheme 48: Resin-bound Ugi-approach towards tetrazole-based peptidomimetics.
Scheme 49: Ugi/cyclization approach towards γ/δ/ε-lactam tetrazoles.
Scheme 50: Ugi-3CR to pipecolic acid-based peptidomimetics.
Scheme 51: Staudinger–Aza-Wittig/Ugi-approach towards pipecolic acid peptidomimetics.
Figure 1: The three structural isomers of diketopiperazines. The 2,5-DKP isomer is most common.
Scheme 52: UDC-approach to obtain 2,5-DKPs, either using Armstrong’s isocyanide or via ethylglyoxalate.
Scheme 53: a) Ugi reaction in water gave either 2,5-DKP structures or spiro compounds. b) The Ugi reaction in ...
Scheme 54: Solid-phase approach towards diketopiperazines.
Scheme 55: UDAC-approach towards DKPs.
Scheme 56: The intermediate amide is activated as leaving group by acid and microwave assisted organic synthes...
Scheme 57: UDC-procedure towards active oxytocin inhibitors.
Scheme 58: An improved stereoselective MCR-approach towards the oxytocin inhibitor.
Scheme 59: The less common Ugi reaction towards DKPs, involving a Sn2-substitution.
Figure 2: Spatial similarities between a natural β-turn conformation and a DKP based β-turn mimetic [158].
Scheme 60: Ugi-based syntheses of bicyclic DKPs. The amine component is derived from a coupling between (R)-N-...
Scheme 61: Ugi-based synthesis of β-turn and γ-turn mimetics.
Figure 3: Isocyanide substituted 3,4-dihydropyridin-2-ones, dihydropyridines and the Freidinger lactams. Bio-...
Scheme 62: The mechanism of the 4-CR towards 3,4-dihydropyridine-2-ones 212.
Scheme 63: a) Multiple MCR-approach to provide DHP-peptidomimetic in two-steps. b) A one-pot 6-CR providing th...
Scheme 64: The MCR–alkylation–MCR procedure to obtain either tetrapeptoids or depsipeptides.
Scheme 65: U-3CR/cyclization employing semicarbazone as imine component gave triazine based peptidomimetics.
Scheme 66: 4CR towards triazinane-diones.
Scheme 67: The MCR–alkylation–IMCR-sequence described by our group towards triazinane dione-based peptidomimet...
Scheme 68: Ugi-4CR approaches followed by a cyclization to thiomorpholin-ones (a) and pyrrolidines (b).
Scheme 69: UDC-approach for benzodiazepinones.
Scheme 70: Ugi/Mitsunobu sequence to BDPs.
Scheme 71: A UDAC-approach to BDPs with convertible isocyanides. The corresponding amide is cleaved by microwa...
Scheme 72: microwave assisted post condensation Ugi reaction.
Scheme 73: Benzodiazepinones synthesized via the post-condensation Ugi/ Staudinger–Aza-Wittig cyclization.
Scheme 74: Two Ugi/cyclization approaches utilizing chiral carboxylic acids. Reaction (a) provided the product...
Scheme 75: The mechanism of the Gewald-3CR includes three base-catalysed steps involving first a Knoevnagel–Co...
Scheme 76: Two structural 1,4-thienodiazepine-2,5-dione isomers by U-4CR/cyclization.
Scheme 77: Tetrazole-based diazepinones by UDC-procedure.
Scheme 78: Tetrazole-based BDPs via a sequential Ugi/hydrolysis/coupling.
Scheme 79: MCR synthesis of three different tricyclic BPDs.
Scheme 80: Two similar approaches both involving an Ugi reaction and a Mitsunobu cyclization.
Scheme 81: Mitsunobu–Ugi-approach towards dihydro-1,4-benzoxazepines.
Scheme 82: Ugi reaction towards hetero-aryl fused 5-oxo-1,4-oxazepines.
Scheme 83: a) Ugi/RCM-approach towards nine-membered peptidomimetics b) Sequential peptide-coupling, deprotect...
Scheme 84: Ugi-based synthesis towards cyclic RGD-pentapeptides.
Scheme 85: Ugi/MCR-approach towards 12–15 membered macrocycles.
Scheme 86: Stereoselective Ugi/RCM approach towards 16-membered macrocycles.
Scheme 87: Passerini/RCM-sequence to 22-membered macrocycles.
Scheme 88: UDAC-approach towards 12–18-membered depsipeptides.
Figure 4: Enopeptin A with its more active derivative ADEP-4.
Scheme 89: a) The Joullié–Ugi-approach towards ADEP-4 derivatives b) Ugi-approach for the α,α-dimethylated der...
Scheme 90: Ugi–Click-strategy for 15-membered macrocyclic glyco-peptidomimetics.
Scheme 91: Ugi/Click combinations provided macrocycles containing both a triazole and an oxazole moiety.
Scheme 92: a) A solution-phase procedure towards macrocycles. b) Alternative solid-phase synthesis as was repo...
Scheme 93: Ugi/cyclization towards cyclophane based macrocycles.
Scheme 94: PADAM-strategy towards eurystatin A.
Scheme 95: PADAM-approach for cyclotheanamide.
Scheme 96: A triple MCR-approach affording RGD-pentapeptoids.
Scheme 97: Ugi-MiBs-approach towards peptoid macrocycles.
Scheme 98: Passerini-based MiB approaches towards macrocycles 345 and 346.
Scheme 99: Macrocyclic peptide formation by the use of amphoteric aziridine-based aldehydes.
Beilstein J. Org. Chem. 2014, 10, 471–480, doi:10.3762/bjoc.10.45
Graphical Abstract
Figure 1: Natural products containing the β-carboline skeletal.
Scheme 1: Retrosynthetic analysis of 6.
Scheme 2: Plausible mechanism of the oxidative amidation for 9.
Scheme 3: Synthesis of α-ketoamide 9.
Scheme 4: Synthesis of dihydroeudistomin Y analogues.
Scheme 5: Plausible mechanism for the formation of 7.
Scheme 6: Rearrangement of 8a into 7a and coupling interactions of 7a.
Figure 2: COSY and HSQC of 8a and 7a.
Beilstein J. Org. Chem. 2014, 10, 155–162, doi:10.3762/bjoc.10.13
Graphical Abstract
Figure 1: Structures of dimebon and SS peptides.
Scheme 1: Synthesis of starting N-substituted tetrahydro-γ-carbolines 3a–d.
Scheme 2: Synthesis of peptides 5 through the Ugi reaction.
Scheme 3: Synthesis of N-substituted tetrahydro-γ-carbolines containing protected peptide residues.
Scheme 4: Synthesis of dihydrochloride salts 7a–g.